Report from Annual General Meeting 2023 of Cereno Scientific AB
The Annual General Meeting of Cereno Scientific AB (publ) was held today June 1, 2023, in the premises of MAQS Advokatbyrå at Östra Hamngatan 24 in Gothenburg. Chairman of the Annual General Meeting (the “AGM”) was Eric Ehrencrona from MAQS Advokatbyrå.
The following main resolutions were resolved at the AGM:
Adoption of income statement and balance sheet for the company and the group
The AGM resolved to adopt the presented income statement and balance sheet for the company and the group.
Allocation of result
The AGM resolved, in accordance with the board of directors’ proposal, that available funds are balanced in the new account and thus no dividends are paid for the financial year 2022.
Discharge from liability
The AGM resolved the discharge from liability for board members and the CEO for the financial year 2022.
Determination of number of board members, deputy board members and the number of auditors and determination of fees to the board and auditors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, that, for the period until the next AGM is held, the board is to be comprised of five members. Fees to the board are to be paid in the amount of SEK 315,000 to the chairman (corresponding to six price base amounts), with SEK 157,500 to each of the other board members (corresponding to three price base amounts). Furthermore, the AGM resolved, in accordance with the nomination committee’s proposal, that for the period until the end of the next AGM, one auditor shall be appointed and that fees to the auditors shall be paid according to invoices approved by the company.
Election of directors, deputies, and auditors
The AGM resolved to re-elect Sverker Jern, Anders Svensson, and Lena Mårtensson as board members and that Jonas Faijerson Säljö and Joakim Södrström be elected as new board members. Joakim Söderström was elected chairman of the board of directors. The AGM resolved to re-elect Frejs Revisorer AB as the company’s auditor. Frejs Revisorer AB has informed the company that Mikael Glimstedt will continue as principal auditor.
Principles for the Nomination Committee
The AGM resolved to adopt the nomination committee’s proposed principles for the nomination committee.
The complete proposal of the nominations committee is available on the company’s website (www.cerenoscientific.com).
Resolution on adoption of new Articles of Association and consolidation of shares
It was noted at the AGM that the board of directors had resolved to withdraw the proposal on the adoption of new Articles of Association and consolidation of shares.
Resolution on authorization for the board of directors to issue shares and/or warrants and/or convertibles
The AGM resolved, in accordance with the board of directors’ proposal, to authorize the board of directors to resolve, on one or several occasions, on issue of shares and/or warrants and/or convertibles during the time until the next AGM.
The complete proposal of the board of directors is available on the website of the company (www.cerenoscientific.com).
For further information, please contact:
Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno Scientific to use their cutting-edge technology CardioMEMS HF System in the study. Cereno Scientific also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno Scientific is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.